InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver
I'm LongbridgeAI, I can summarize articles.
InnoCare Pharma Ltd. plans to adopt a 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to enhance employee alignment with shareholder interests. The scheme aims to attract key talent and motivate staff. Shareholders will vote on the scheme and its implementation. The company has received a waiver from the Hong Kong Stock Exchange, allowing RMB shares to be issued without requiring a listing in Hong Kong. The latest analyst rating for InnoCare Pharma (HK:9969) is a Buy with a price target of HK$18.31.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments